Allergen immunotherapy

Journal of Allergy and Clinical Immunology

Volumn 125, Issue 2 SUPPL. 2, 2010, Pages

  Frew, Anthony J ^a  

^a BRIGHTON AND SUSSEX MEDICAL SCHOOL   (United Kingdom)

Author keywords

asthma; B cell; IgE; IgG; immunomodulation; Immunotherapy; rhinitis; sublingual; T cell

Indexed keywords

ALLERGEN; EPITOPE; GAMMA INTERFERON; GRASS POLLEN EXTRACT; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G4; INTERLEUKIN 12; INTERLEUKIN 2; WASP VENOM;

ALLERGIC RHINITIS; ANTIBODY PRODUCTION; ARTICLE; ASTHMA; B LYMPHOCYTE; BEE STING; BRONCHOSPASM; CD4+ T LYMPHOCYTE; CLONAL ANERGY; DESENSITIZATION; GRASS POLLEN; HUMAN; HYPERSENSITIVITY; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; RISK ASSESSMENT; SENSITIZATION; SKIN SENSITIVITY; TH1 CELL; TH2 CELL; TREATMENT INDICATION; TREATMENT RESPONSE;

ADMINISTRATION, SUBLINGUAL; ALLERGENS; DESENSITIZATION, IMMUNOLOGIC; HUMANS; HYPERSENSITIVITY; IMMUNE TOLERANCE; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL;

EID: 76749116985     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2009.10.064     Document Type: Article

References (59)

1. Freeman J. Vaccination against hay fever: report of results during the first three years. Lancet 1 (1914) 1178
2. Creticos P.S., Van Metre T.E., Mardiney M.R., Rosenberg G.L., Norman P.S., and Adkinson N.F. Dose-response of IgE and IgG antibodies during ragweed immunotherapy. J Allergy Clin Immunol 73 (1984) 94-104
3. Iliopoulos O., Proud D., Adkinson N.F., Creticos P.S., Norman P.S., Kagey-Sobotka A., et al. Effects of immunotherapy on the early, late and rechallenge nasal reaction to provocation with allergen: changes in inflammatory mediators and cells. J Allergy Clin Immunol 87 (1991) 855-866
4. Francis J., James L., Paraskevopoulos G., Wong C., Calderon M.A., Durham S.R., et al. Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity. J Allergy Clin Immunol 121 (2008) 1120-1125 e2
5. Durham S.R., Ying S., Varney V.A., Jacobson M.R., Sudderick R.M., Mackay I.S., Kay A.B., et al. Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T-lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing mRNA for interferon-gamma. J Allergy Clin Immunol 97 (1996) 1356-1365
6. McHugh S.M., Deighton J., Stewart A.G., Lachmann P.J., and Ewan P.W. Bee venom immunotherapy induces a shift in cytokine responses from a Th2 to a Th1 dominant pattern: comparison of rush and conventional immunotherapy. Clin Exp Allergy 25 (1995) 828-838
7. Ebner C., Siemann U., Bohle B., Willheim M., Wiedermann U., Schenk S., et al. Immunological changes during specific immunotherapy of grass pollen allergy: reduced lymphoproliferative responses to allergen and shift from Th2 to Th1 in T-cell clones specific for Phl p1, a major grass pollen allergen. Clin Exp Allergy 27 (1997) 1007-1015
8. Jutel M., Akdis M., Blaser K., and Akdis C.A. Mechanisms of allergen specific immunotherapy-T-cell tolerance and more. Allergy 61 (2006) 796-807
9. Nasser S.M., Ying S., Meng Q., Kay A.B., and Ewan P.W. IL-10 levels increase in cutaneous biopsies of patients undergoing wasp venom immunotherapy. Eur J Immunol 31 (2001) 3704-3713
10. Akdis C.A., Blesken T., Akdis M., Wuthrich B., and Blaser K. Role of IL-10 in specific immunotherapy. J Clin Invest 102 (1998) 98-106
11. Bellinghausen I., Knop J., and Saloga J. The role of IL-10 in the regulation of allergic immune responses. Int Arch Allergy Appl Immunol 126 (2001) 97-101
12. Graft D.F. Insect sting allergy. Med Clin North Am 90 (2006) 211-232
13. Golden D.B., Marsh D.G., Freidhoff L.R., Kwiterovich K.A., Addison B., Kagey-Sobotka A., et al. Natural history of hymenoptera venom sensitivity in adults. J Allergy Clin Immunol 100 (1997) 760-766
14. Calderon M.A., Alves B., Jacobson M., Hurwitz B., Sheikh A., and Durham S. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev 1 (2007) CD001936
15. Frew A.J., Powell R.M., Corrigan C.J., and Durham S.R. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 117 (2006) 319-325
16. Naclerio R.M., Proud D., Moylan B., Balcer S., Freidhoff L., Kagey-Sobotka A., et al. A double blind study of the discontinuation of ragweed immunotherapy. J Allergy Clin Immunol 100 (1997) 293-300
17. Durham S.R., Walker S.M., Varga E.M., Jacobson M.R., O'Brien F., Nobel W., et al. Long-term clinical efficacy of grass pollen immunotherapy. N Engl J Med 341 (1999) 468-475
18. Eng P.A., Borer-Reinhold M., Heijnen I.A., and Gnehm H.P. Twelve-year follow-up after discontinuation of preseasonal grass pollen immunotherapy in childhood. Allergy 61 (2006) 198-201
19. Varney V.A., Edwards J., Tabbah K., Brewster H., Mavroleon G., and Frew A.J. Clinical efficacy of specific immunotherapy to cat dander: a double blind placebo controlled trial. Clin Exp Allergy 27 (1997) 860-867
20. White P.J., Smith H.E., Baker N., Davis W., and Frew A.J. Symptom control in patients with hay fever in UK general practice: how well are we doing and is there a need for allergen immunotherapy?. Clin Exp Allergy 28 (1998) 266-270
21. Bousquet J., Lockey R.F., and Malling H.J. WHO position paper. Allergen immunotherapy: therapeutic vaccines for allergic disease. Allergy 53 suppl (1998) 1-42
22. Abramson M., Puy R., and Weiner J. Immunotherapy in asthma: an updated systematic review. Allergy 54 (1999) 1022-1041
23. Creticos P.S., Reed C.E., Norman P.S., Khoury J., Adkinson N.F., Buncher C.R., et al. Ragweed immunotherapy in adult asthma. N Engl J Med 334 (1996) 501-506
24. Lilja G., Sundin B., Graff-Lonnevig V., Hedlin G., Heilborn H., Norrlind K., et al. Immunotherapy with partially purified and standardised animal dander extracts. IV. Effects of 2 years of treatment. J Allergy Clin Immunol 83 (1989) 37-44
25. Adkinson N.F., Eggleston P.A., Eney D., Goldstein E.O., Schuberth K.C., Bacon J.R., et al. A controlled trial of immunotherapy for asthma in allergic children. N Engl J Med 336 (1997) 324-331
26. Des Roches A., Paradis L., Menardo J.L., Bouges S., Daures J.P., and Bousquet J. Immunotherapy with a standardised Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitisations in children. J Allergy Clin Immunol 99 (1997) 450-453
27. Horak F. Manifestation of allergic rhinitis in latent sensitised patients. A prospective study. Arch Otorhinolaryngol 242 (1985) 242-249
28. Niggemann B., Jacobsen L., Dreborg S., Ferdousi H.A., Halken S., Host A., et al. Five-year follow-up on the PAT study: specific immunotherapy and long-term prevention of asthma in children. Allergy 61 (2006) 855-859
29. Johnstone D.E., and Dutton A. The value of hyposensitization therapy for bronchial asthma in children. A 14 year study. Pediatrics 42 (1968) 793-802
30. Shaikh W.A. Immunotherapy vs inhaled budesonide in bronchial asthma: an open parallel comparative trial. Clin Exp Allergy 27 (1997) 1279-1284
31. Committee on the Safety of Medicines. CSM update: immunotherapy. BMJ 293 (1986) 948
32. Stewart G.E., and Lockey R.F. Systemic reactions from allergen immunotherapy. J Allergy Clin Immunol 90 (1992) 567-578
33. Bernstein D.I., Wanner M., Borish L., and Liss G.M. Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001. J Allergy Clin Immunol 113 (2004) 1129-1136
34. Wilson D.R., Lima M.T., and Durham S.R. Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy 60 (2005) 4-12
35. Dahl R., Kapp A., Colombo G., de Monchy J.G., Rak S., Emminger W., et al. Efficacy and safety of sublingual immunotherapy with once daily grass allergen tablets for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 118 (2006) 434-440
36. Alvarez-Cuesta E., Berges-Gimeno P., Mancebo E.G., Fernandez-Caldas E., Cuesta-Herranz J., and Casanovas M. Sublingual immunotherapy with a standardised cat dander extract: evaluation of efficacy in a double-blind placebo-controlled study [published erratum in Allergy 2007;62:1100]. Allergy 62 (2007) 810-817
37. Di Rienzo V., Marcucci F., Puccinelli P., Parmiani S., Frati F., Sensi L., et al. Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: a 10 year prospective study. Clin Exp Allergy 33 (2003) 206-210
38. Bufe A., Ziegler-Kirbach E., Stoeckmann E., Heidemann P., Gehlhar K., Holland-Letz T., et al. Efficacy of sublingual swallow immunotherapy in children with severe grass pollen allergic symptoms: a double-blind placebo-controlled study. Allergy 59 (2004) 498-504
39. Bachert C., Vestenbaek U., Christensen J., Griffiths U.K., and Poulsen P.B. Cost-effectiveness of grass allergen tablet (GRAZAX) for the prevention of seasonal grass-pollen-induced rhinoconjunctivitis-a Northern European perspective. Clin Exp Allergy 37 (2007) 772-779
40. Khinchi M.S., Poulsen L.K., Carat F., Andre C., Hansen A.B., and Malling H.J. Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized, placebo-controlled, double-blind, double-dummy study. Allergy 59 (2004) 45-53
41. Mauroa M., Russelloa M., Incorvaiab C., Gazzolaa G.B., Di Carac G., and Frati F. Comparison of efficacy, safety and immunologic effects of subcutaneous and sublingual immunotherapy in birch pollinosis: a randomized study. Allerg Immunol (Paris) 39 (2007) 119-122
42. Reilly D.T., Taylor M.A., McSharry C., and Aitchison T. Is homeopathy a placebo response? Controlled trial of homeopathic potency with pollen in hay fever as a model. Lancet 2 (1986) 881-886
43. Lewith G.T., Watkins A.D., Hyland M.E., Shaw S., Broomfield J.A., Dolan G., et al. Use of ultramolecular potencies of allergen to treat asthmatic people allergic to house dust mite: double blind randomised controlled clinical trial. BMJ 324 (2002) 520
44. Pauli G., Larsen T.H., Rak S., Horak F., Pastorello E., Valenta R., et al. Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis. J Allergy Clin Immunol 122 (2008) 951-960
45. Valenta R., and Niederberger V. Recombinant allergens for immunotherapy. J Allergy Clin Immunol 119 (2007) 826-830
46. Purohit A., Niederberger V., Kronqvist M., Horak F., Gronneberg R., Suck R., et al. Clinical effects of immunotherapy with genetically modified recombinant birch pollen Bet v1 derivatives. Clin Exp Allergy 38 (2008) 1514-1525
47. O'Hehir R.E., Yssel H., Verma S., de Vries J.E., Spits H., and Lamb J.R. Clonal analysis of differential lymphokine production in peptide and superantigen-induced T-cell anergy. Int Immunol 3 (1991) 819-826
48. Fasler S., Aversa G., de Vries J.E., and Yssel H. Antagonistic peptides specifically inhibit proliferation, cytokine production, CD40L expression and help for IgE synthesis by Der p 1-specific human T-cell clones. J Allergy Clin Immunol 101 (1998) 521-530
49. Wiedermann U., Herz U., Baier K., Vrtala S., Neuhaus-Steinmetz U., Bohle B., et al. Intranasal treatment with a recombinant hypoallergenic derivative of the major birch pollen allergen Bet v 1 prevents allergic sensitization and airway inflammation in mice. Int Arch Allergy Immunol 126 (2001) 68-77
50. Shirakawa T., Enomoto T., Shimazu S.I., and Hopkin J.M. The inverse association between tuberculin responses and atopic disorder. Science 275 (1997) 77-79
51. Strannegaard I.L., Larsson L.O., Wennergren G., and Strannegaard O. Prevalence of allergy in children in relation to prior BCG vaccination and infection with atypical mycobacteria. Allergy 53 (1998) 249-254
52. Erb K.J., Holloway J.W., Sobeck A., Moll H., and Le Gros G. Infection of mice with Mycobacterium bovis-BCG suppresses allergen-induced airways eosinophilia. J Exp Med 187 (1998) 561-569
53. Kline J.N., Waldschmidt T.J., Businga T.R., Lemish J.E., Weinstock J.V., Thorne P.S., et al. Modulation of airway inflammation by CpG oligodeoxynucleotides in a murine model of asthma. J Immunol 160 (1998) 2555-2559
54. Sur S., Wild J.S., Choudury B.K., Sur N., Alam R., and Klinman D.M. Long-term prevention of allergic lung inflammation in a mouse model of asthma by CpG oligodeoxynucleotides. J Immunol 162 (1999) 6284-6293
55. Tighe H., Takabayashi K., Schwartz D., van Nest G., Tuck S., Eiden J.J., et al. Conjugation of immunostimulatory DNA to the short ragweed allergen Amb a 1 enhances its immunogenicity and reduces its allergenicity. J Allergy Clin Immunol 106 (2000) 124-134
56. Marshall J.D., Abtahi S., Eiden J.J., Tuck S., Milley R., Haycock F., et al. Immunostimulatory sequence DNA linked to the Amb a 1 allergen promotes Th1 cytokine expression while downregulating Th2 cytokine expression in PBMCs from human patients with ragweed allergy. J Allergy Clin Immunol 108 (2001) 191-197
57. Creticos P.S., Eiden J.J., Broide D., Balcer-Whaley S.L., Schroeder J.T., Khattignavong A., et al. Immunotherapy with immunostimulatory oligonucleotides linked to purified ragweed Amb a 1 allergen: effects on antibody production, nasal allergen provocation and ragweed seasonal rhinitis. J Allergy Clin Immunol 109 (2002) 743-744
58. Hsu C.H., Chua K.Y., Tao M.H., Lai Y.L., Wu H.D., Huang S.K., et al. Immunoprophylaxis of allergen-induced IgE synthesis and airway hyperresponsiveness in vivo by genetic immunisation. Nat Med 2 (1996) 540-544
59. Hartl A., Kiesslich J., Weiss R., Bernhaupt A., Mostbock S., Scheiblhofer S., et al. Immune responses after immunisation with plasmid DNA encoding Bet v 1, the major allergen of birch pollen. J Allergy Clin Immunol 103 (1999) 107-113